<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000857.v1.p1" parentStudy="phs000857.v1.p1" createDate="2015-01-13" modDate="2015-04-27">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Levi A. Garraway</td><td>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Carlos Arteaga</td><td>Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole</StudyNameEntrez>
	<StudyNameReportPage>Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Clinical Trial</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>These are tumor biopsies and corresponding normal samples from patients with early stage ER+/HER2- breast cancer who had received the aromatase inhibitor letrozole for 10-21 days prior to surgery.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>All patients had early stage ER+/HER2- breast cancer and participated in a clinical trial of neoadjuvant letrozole for 10-21 days prior to surgery.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Breast Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Levi A. Garraway</AttName>
			<Institution>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Carlos Arteaga</AttName>
			<Institution>Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-PUB-NPU" longName="Health/Medical/Biomedical (PUB, NPU)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000857.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000857.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000857.v1.p1" FileName="DUC_Garraway_Breast_Cancer_Vanderbilt_Jan2015.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (PUB, NPU)</ConsentName>
        <ConsentAbbrev>HMB-PUB-NPU</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor agrees to make results of studies using the data available to the larger scientific community.
Use of the data is limited to not-for-profit organizations.
Use of this data is limited to health/biomedical/medical purposes. Use of this data is limited to not-for-profit organizations. Investigators must state in the Data Access Request their intention to publish or otherwise broadly share any finding form his/her study with the scientific community</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
